COIOSDeep risk insights through multi-disciplinary research across the globe
closeup photo of assorted-color stone lot
Item confirms Peer-reviewed Added

Empagliflozin's lower cardiovascular risk is similar across social groups in Medicare

In US Medicare claims, empagliflozin initiators aged 65 and over had a hazard ratio of 0.77 for major cardiovascular events against DPP-4 inhibitors, with no variation by social group.

Analysis of 2014-2020 US Medicare claims matched empagliflozin initiators aged 65 and over with type 2 diabetes against DPP-4 inhibitor and GLP-1 initiators. Against DPP-4 inhibitors, the hazard ratio was 0.72 for admission with heart failure and 0.66 for death from any cause. Absolute benefit was larger in those with existing cardiovascular disease, and similar across sex, race and socioeconomic measures.

Why it is interesting: Absolute benefit sits with those who already have cardiovascular disease, not with any particular social group.

Source
Diabetes Care, 21 September 2026
Paper
Effects of Empagliflozin on Cardiovascular Outcomes Are Consistent Across Sociodemographic Subgroups: A Real-World Analysis From the EMPRISE Study
Authors
Cromer SJ, Tesfaye H, Cho H, Wexler DJ, Ortega-Montiel J, Schmedt N et al.
DOI
10.2337/dca26-0039
Type
Peer-reviewed article
Design
Propensity score-matched new-user cohort in US Medicare claims, 2014-2020, adults aged 65 and over with type 2 diabetes
Verdict
Confirms prior evidence
Driver
Heart and stroke
Driver
Obesity, diabetes and GLP-1

Other drivers in Health today